Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.

导出原文传递

翻译打印收藏纠错

作者： Jin-Young,Jang ^[1] ; Youngmin,Han ^[1] ; Hongeun,Lee ^[1] ; Sun-Whe,Kim ^[1] ; Wooil,Kwon ^[1] ; Kyung-Hun,Lee ^[2] ; Do-Youn,Oh ^[2] ; Eui Kyu,Chie ^[3] ; Jeong Min,Lee ^[4] ; Jin Seok,Heo ^[5] ; Joon Oh,Park ^[6] ; Do Hoon,Lim ^[7] ; Seong Hyun,Kim ^[8] ; Sang Jae,Park ^[9] ; Woo Jin,Lee ^[9] ; Young Hwan,Koh ^[9] ; Joon Seong,Park ^[10] ; Dong Sup,Yoon ^[10] ; Ik Jae,Lee ^[11] ; Seong Ho,Choi ^[5]

作者单位： Department of Surgery, Seoul National University Hospital, Seoul, Republic of Korea. ^[1] Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. ^[2] Department of Radiation Oncology, Seoul National University Hospital, Seoul, Republic of Korea. ^[3] Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea. ^[4] Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. ^[5] Department of Internal Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. ^[6] Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. ^[7] Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. ^[8] Center for Liver Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea. ^[9] Department of Surgery, Gangnam Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea. ^[10] Department of Radiation Oncology, Yonsei University Health System, Seoul, Republic of Korea. ^[11]